Drug Profile
Benzocaine otic solution
Alternative Names: AR-01Latest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator Arbor Pharmaceuticals
- Class Aminobenzoic acids; Benzoates; Local anaesthetics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 23 Jun 2014 Discontinued - Phase-III for Pain (In adolescents, In children) in USA (Otic)
- 01 Mar 2014 Arbor Pharmaceuticals completes a phase III trial in Otitis media (in paediatric patients) in USA (NCT02044341)
- 31 Dec 2013 Arbor Pharmaceuticals initiates enrolment in two phase III trials for Otitis media (in paediatric patients) in USA (NCT02044341 & NCT02074007)